Uterine cancer — also called endometrial cancer, as it most commonly originates in the endometrium (the lining of the uterus) — is the most commonly diagnosed gynecologic cancer in the United States. The majority of uterine cancer diagnoses occur at early stages because abnormal bleeding typically prompts early evaluation. Early-stage uterine cancer survivors, particularly those with low-grade endometrioid tumors, are among the more insurable cancer survivors, with meaningful options for standard coverage after sufficient remission time. Higher-grade and later-stage disease presents more significant underwriting challenges. This guide covers the key factors insurers evaluate and what to expect at different stages.

Uterine Cancer vs. Endometrial Cancer: A Terminology Note

The terms "uterine cancer" and "endometrial cancer" are often used interchangeably in general usage, and most life insurance applications will ask about both. Technically, uterine cancer can refer to any cancer originating in the uterus, including the more rare uterine sarcomas (such as leiomyosarcoma or carcinosarcoma/MMMT). Endometrial carcinoma — the most common type — originates in the endometrial lining. This distinction matters for underwriting because uterine sarcomas have significantly different prognoses and underwriting outcomes than endometrial carcinomas, even at equivalent stages. This guide focuses primarily on endometrial carcinoma but includes notes on sarcomas where relevant.

Key Factors Underwriters Evaluate for Uterine Cancer

Stage at Diagnosis

Uterine cancer is staged using the FIGO system (Stages I through IV):

  • Stage IA (tumor limited to endometrium or less than half myometrial invasion): The most common and most favorable underwriting scenario for uterine cancer. Many women are diagnosed at Stage IA due to early symptom presentation. Standard coverage is often available after 2–3 years of clean follow-up for low-grade Stage IA endometrioid carcinoma. Five-year survival rates for Stage I uterine cancer are generally estimated at 85–95%.
  • Stage IB (half or more myometrial invasion, still confined to uterus): Somewhat less favorable than Stage IA. Standard coverage is typically available after 3–5 years of sustained clean surveillance. Table ratings are common in earlier years.
  • Stage II (cervical stromal invasion): Standard coverage typically requires 5+ years of clean follow-up. Table ratings are expected. Simplified issue is a practical option during earlier years.
  • Stage III (regional spread to adnexa, vagina, lymph nodes, or serosa): Standard coverage typically requires 5–7 years of clean follow-up at most carriers. Simplified issue may be available after 3–5 years. Guaranteed issue is the most accessible near-term option for most Stage III survivors.
  • Stage IV (bladder/bowel involvement or distant metastasis): Standard and simplified issue coverage are generally not available near-term. Guaranteed issue and group coverage are the most accessible options.

Histologic Type

The histologic type of uterine cancer has a major impact on underwriting outcomes — arguably as important as stage in some cases:

  • Endometrioid carcinoma (Type I): The most common type, accounting for approximately 80% of uterine cancers. Associated with estrogen exposure and often diagnosed at early stages. Low-grade endometrioid carcinoma (Grade 1–2) has the most favorable underwriting prospects of any uterine cancer type. Even moderately experienced underwriters are familiar with this subtype.
  • Serous carcinoma (Type II): More aggressive behavior than endometrioid. Associated with TP53 mutations. Behaves more like ovarian cancer and is underwritten more conservatively even at early stages. Standard coverage may require longer waiting periods.
  • Clear cell carcinoma (Type II): Also more aggressive, underwritten conservatively. Similar to serous in terms of required waiting periods.
  • Carcinosarcoma/MMMT (malignant mixed Müllerian tumor): Highly aggressive. Among the most difficult uterine cancer types for underwriting. Standard coverage may not be available even after extended remission at many carriers.
  • Uterine leiomyosarcoma: Aggressive sarcoma arising from the smooth muscle of the uterus. Underwritten very conservatively. Standard coverage is generally not available near-term even after apparent remission, due to high recurrence rates.

Grade

For endometrioid carcinoma, histologic grade is one of the most important underwriting factors alongside stage:

  • Grade 1 (well differentiated): Most favorable. Low-grade endometrioid tumors at Stage IA–IB often have the best underwriting prospects among uterine cancers.
  • Grade 2 (moderately differentiated): Intermediate. Underwriting generally somewhat less favorable than Grade 1 but significantly better than Grade 3.
  • Grade 3 (poorly differentiated): More aggressive. Treated more similarly to Type II tumors from an underwriting perspective. Longer waiting periods expected.

Lymph Node Status

For surgically staged uterine cancer, lymph node status is a critical prognostic factor. Negative pelvic and para-aortic lymph nodes (pN0) is a strong favorable signal. Positive lymph nodes significantly affect underwriting timelines, even for otherwise early-stage disease. If sentinel lymph node biopsy was performed and results were negative, document this specifically — it may be viewed more favorably than traditional lymphadenectomy results at some carriers.

Treatment Received

  • Total hysterectomy with bilateral salpingo-oophorectomy (TH-BSO): Standard surgical treatment for most uterine cancers. Negative margins and negative nodes are the key positive underwriting signals.
  • Minimally invasive surgery (laparoscopic or robotic): Increasingly standard. No underwriting difference from open surgery when the same staging procedures are completed.
  • Adjuvant vaginal brachytherapy: Sometimes used for Stage IB Grade 3 or Stage II disease. Indicates slightly higher-risk disease but is a well-accepted adjuvant treatment.
  • External beam radiation therapy (EBRT): Used for higher-stage or higher-risk disease. Indicates more advanced disease than surgery alone.
  • Chemotherapy (carboplatin/paclitaxel): Standard for Stage III–IV disease or high-risk histologies. Indicates higher-risk disease.
  • Hormone therapy (progestins): Sometimes used for low-grade endometrioid tumors in women wishing to preserve fertility, or for recurrent disease. Fertility-sparing treatment in early-stage disease is a less common scenario from an underwriting perspective.

Remission Duration and Surveillance Compliance

Follow-up after uterine cancer treatment typically includes pelvic exams every 3–6 months for 2–3 years, then annually, along with symptom review and periodic imaging if indicated. Consistent attendance at all follow-up appointments and clean results are the most important positive signals for underwriters. Documented compliance is as important as the clean results themselves.

Approximate Waiting Periods and Coverage Outlook

Stage IA, Grade 1–2 Endometrioid, TH-BSO, Negative Nodes, No Adjuvant Treatment

The most favorable uterine cancer underwriting scenario. Some carriers will consider applications 1–2 years after surgery. Standard or near-standard coverage is achievable after 2–3 years of clean follow-up at favorable carriers. This profile is more insurable than many survivors expect.

Stage IB, Grade 1–2 Endometrioid, Surgery with or Without Vaginal Brachytherapy

Standard coverage typically available after 3–5 years of clean follow-up. Table ratings common in earlier years. Simplified issue is practical during the 1–3 year post-treatment window.

Stage I–II, Grade 3 Endometrioid or Type II Histology

More conservative underwriting. Standard coverage typically requires 5+ years of clean follow-up. Simplified issue may be available after 3 years at favorable carriers. Table ratings expected even after the waiting period.

Stage III, Any Histology

Standard coverage typically requires 5–7 years of clean surveillance. Simplified issue may be available after 3–5 years. Guaranteed issue is the most accessible near-term option for most Stage III survivors.

Stage IV or Uterine Sarcoma

Standard and simplified issue coverage are generally not available near-term. Guaranteed issue and group coverage are the most accessible options. Uterine sarcomas — particularly leiomyosarcoma — are underwritten very conservatively even after extended remission at most carriers.

Lynch Syndrome and Hereditary Uterine Cancer

Approximately 2–5% of endometrial cancers are associated with Lynch syndrome (hereditary nonpolyposis colorectal cancer, or HNPCC). If your uterine cancer occurred in the context of Lynch syndrome — suggested by young age at diagnosis, family history of colorectal or endometrial cancer, or tumor testing showing microsatellite instability (MSI-High) — underwriters may ask about genetic testing results and ongoing surveillance plans for Lynch-associated cancers (particularly colorectal). Document your genetic counseling and testing results. Mismatch repair deficiency (dMMR) in your tumor may have implications for targeted therapy eligibility but also for underwriting risk assessment.

Practical Steps Before Applying

  1. Obtain complete medical records. Pathology report (including histologic type, FIGO grade, myometrial invasion depth, lymphovascular space invasion status, lymph node results, and margin status), operative note, and any adjuvant treatment summaries.
  2. Know your exact stage, histologic type, and grade. "Stage I uterine cancer" is not specific enough. Know your FIGO stage (IA vs. IB), histologic type (endometrioid vs. serous vs. other), grade (1, 2, or 3), and lymph node status.
  3. Document all follow-up visits and results. Every clean pelvic exam is a positive signal. Bring visit records, not just a physician summary letter.
  4. Work with an independent broker specializing in impaired risk. Uterine cancer underwriting is highly type- and grade-specific. A specialist knows which carriers apply the most favorable guidelines for your specific profile.
  5. Consider timing. If you're approaching a standard waiting period threshold, waiting a few additional months may significantly improve your options and rates.

How Much Coverage Do You Need?

Coverage need is based on your financial situation — income, debts, and dependents — not health history. Use our Life Insurance Calculator to estimate the right amount before approaching insurers.

Other Cancer Guides in This Series

Bottom Line

Uterine cancer survivors — particularly those with low-grade endometrioid tumors diagnosed at early stages — are often more insurable than they expect. The key underwriting factors are histologic type, grade, stage, lymph node status, and sustained remission duration. Early-stage, low-grade endometrioid carcinoma has some of the most favorable life insurance underwriting outcomes among gynecologic cancers. Higher-grade and higher-stage disease, and especially uterine sarcomas, face more conservative underwriting, but meaningful options remain through simplified issue, graded benefit, and guaranteed issue policies. An independent broker with impaired-risk expertise is the most important resource in navigating insurer-specific guidelines and finding the best available coverage for your specific profile.

This content is for informational purposes only and does not constitute insurance, financial, or legal advice. Insurance options vary by carrier, state, and individual health history. Always consult a licensed insurance professional before making coverage decisions.